BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

BNP Paribas Financial Markets purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 193,748 shares of the company's stock, valued at approximately $1,130,000. BNP Paribas Financial Markets owned 0.34% of Olema Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in Olema Pharmaceuticals by 658.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company's stock valued at $2,162,000 after acquiring an additional 157,171 shares during the period. Renaissance Technologies LLC grew its stake in Olema Pharmaceuticals by 435.0% in the 4th quarter. Renaissance Technologies LLC now owns 157,300 shares of the company's stock valued at $917,000 after acquiring an additional 127,900 shares during the period. HighTower Advisors LLC acquired a new stake in Olema Pharmaceuticals in the 4th quarter valued at $510,000. Boothbay Fund Management LLC grew its stake in Olema Pharmaceuticals by 10.8% in the 4th quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company's stock valued at $182,000 after acquiring an additional 3,056 shares during the period. Finally, Alliancebernstein L.P. grew its stake in Olema Pharmaceuticals by 77.7% in the 4th quarter. Alliancebernstein L.P. now owns 313,982 shares of the company's stock valued at $1,831,000 after acquiring an additional 137,319 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Olema Pharmaceuticals Trading Down 2.3%

OLMA traded down $0.12 on Monday, hitting $5.04. 519,216 shares of the company's stock were exchanged, compared to its average volume of 861,382. Olema Pharmaceuticals, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $16.62. The firm has a 50-day moving average price of $4.38 and a 200-day moving average price of $5.74. The stock has a market cap of $344.84 million, a price-to-earnings ratio of -2.30 and a beta of 2.03.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. On average, equities analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Friday, March 28th. Oppenheimer lowered their target price on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Monday, April 28th. Finally, The Goldman Sachs Group lowered their target price on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.